Method of treating hemolytic disease
AssigneeAlexion Pharmaceuticals, Inc.
InventorsLeonard Bell, Russell P. Rother
Life of this patent
Estimating the term…
Abstract
Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.
Claims16
1-130. (canceled)
A method for treating paroxysmal nocturnal hemoglobinuria (PNH), the method comprising administering to a patient with PNH an anti-C5 antibody in an amount and with a frequency effective to maintain a serum concentration of the antibody of about 35 μg/ml to thereby maintain serum complement activity in the patient at a level below 20% of the normal serum complement activity.
A method for treating paroxysmal nocturnal hemoglobinuria (PNH), the method comprising administering to a patient with PNH an anti-C5 antibody at least once every 12 days to thereby maintain in the patient a serum complement activity at a level below 20% of the normal serum complement activity.
A method for treating paroxysmal nocturnal hemoglobinuria (PNH), the method comprising administering to a patient with PNH an anti-C5 antibody under the following dosing schedule:
- (i) 600 mg of the antibody each week for four weeks;
- (ii) 900 mg of the antibody on the fifth week;
- and thereafter,
- (iii) 900 mg of the antibody at least once every 12 days,
- wherein the dosing schedule is effective to maintain in the patient a serum complement activity at a level below 20% of the normal serum complement activity.
Dependencies are inferred from the claim text.